January | February | March | April | May | June | Pending COMPLETED MERGERS AND ACQUISITIONS - June 2013 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details RVX Therapeutics Inc. Zenith Epigenetics Corp. 5/2/13 6/5/13 ND Resverlogix Corp. completed its spin-out of RVX to Zenith COMPLETED MERGERS AND ACQUISITIONS - May 2013 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M

January | February | March | April | May | June | June - 2013 Biotech Company Pharma Company Type/Product Area Terms/Details BeiGene Co. Ltd. Merck KGaA Licensing agreement for a second-generation BRAF inhibitor as a promising preclinical oncology candidate for melanoma, colorectal cancer and other cancers The deal includes an undisclosed up-front payment to BeiGene, plus up to $233M in development and commercial (China) milestones, plus double-digit royalties Biolinerx Ltd

Public Companies | Private Companies PUBLIC COMPANIES - June 2013 Company Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (US$M) Anacor Pharmaceuticals Inc. Loan N/A $7.4 BioTime Inc. Private placement of units 2.2S and 0.545W $9.1 Celsion Corp. At-the-market registered direct offering 6.26S $9.83 InVivo Therapeutics Holdings Corp. Warrant exercise N/A $16.1 StemCells Inc. Three-year stock sale agreement N/A $3 Valneva

Commenced Trading | Filed and Pending COMMENCED TRADING - May 2013 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) Alcobra Ltd. (ADHD) 3/19/13 5/22/13 3.125S $8 11.13 $25 Ambit Biosciences Inc. (AMBI) 2/20/13 5/16/13 8.125S $8 17.7 $65 Epizyme Inc. (EPZM) 4/26/13 5/31/13 5.142S $15 27.64 $88.7 Erytech Pharma SA (Paris:ERYP) 5/14/13 5/14/13 1.53S E11.60 ($14.97) 5.54 E16.7 ($21.6

Follow-on Offerings FOLLOW-ON OFFERINGS - June 2013 Company Date Filed Date Comm. Shares/Units (M) Price Gross (M) Array BioPharma Inc. (ARRY) 6/3/13 6/5/13 Convertible senior notes N/A $132.25 Cempra Inc. (CEMP) 3/22/13 6/14/13 7.2S $7 $50.75 Clovis Oncology Inc. (CLVS) 6/11/13 6/12/13 3.82S $72 $275 Mast Therapeutics Inc. (MSTX) 6/14/13 6/14/13 50U $0.50 $25 FOLLOW-ON OFFERINGS - May 2013 Company Date Filed Date Comm

January | February | March | April | May | June | June - 2013 Company Company Type/Product Area Terms/Details Algeta ASA Avipep Pty Ltd. Collaboration to evaluate a targeted thorium conjugate based on combining Algeta's thorium-227 alpha-pharmaceutical payload with a next-generation antibody fragment, known as an avibody, from Avipep that targets a number of solid tumor types Both companies will contribute financially to the collaboration, which is expected to last for up to

January | February | March | April | May | June | July | August | September | October | November | December | December - 2012 Company Company Type/Product Area Terms/Details Amarantus BioScience Inc. Power3 Medical Products Inc. Deal to buy all of the intellectual property assets from Power3, giving Amarantus the ability to acquire IP for the diagnosis of multiple neurodegenerative diseases and oncology Amarantus is paying $40,000, and the deal includes five patents and 20

Follow-on Offerings FOLLOW-ON OFFERINGS - December 2012 Company Date Filed Date Comm. Shares/Units (M) Price Gross (M) AcelRx Pharmaceuticals Inc. (ACRX) 12/7/12 12/7/12 12.5S $3.31 $41.38 Array BioPharma Inc. (ARRY) 1/13/12 12/7/12 2.7S $3.65 $9.85 (overallotment) Arrowhead Research Corp. (ARWR) 8/17/11 12/10/12 1.8U $2.26 $4.3 Cytori Therapeutics Inc. (CYTX) 5/9/11 12/14/12 7S $2.85 $20 Derma Sciences Inc. (DSCI) 5/20/11 12/7/12

Commenced Trading | Filed and Pending COMMENCED TRADING - December 2012 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) No initial public offerings were completed in December. COMMENCED TRADING - November 2012 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) No initial public offerings were completed in November. COMMENCED TRADING - October 2012 INITIAL OFFERINGS

Public Companies | Private Companies PUBLIC COMPANIES - December 2012 Company Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (US$M) Amarin Corp. plc Investment N/A $100 Arno Therapeutics Inc. Private placements of senior convertible debentures and warrants N/A $2.15 Cel-Sci Corp. Registered direct offering 35S and W for 26.25S $10.5 Cyclacel Pharmaceuticals Inc. Common stock purchase agreement N/A $1 GeneNews Ltd. Private

January | February | March | April | May | June | July | August | September | October | November | December | December - 2012 Biotech Company Pharma Company Type/Product Area Terms/Details AIMM Therapeutics NV Cosmo Pharmaceuticals SpA Strategic partnership to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases including colon carcinoma Cosmo will formulate human monoclonal antibodies generated by AIMM in an extended-release form exploiting its MMX

January | February | March | April | May | June | July | August | September | October | November | December COMPLETED MERGERS AND ACQUISITIONS - December 2012 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details DeCode Genetics Amgen Inc. 12/11/12 12/11/12 $415 Amgen is acquiring DeCode for $415M DUSA Pharmaceuticals Inc. Sun Pharmaceutical Industries Ltd. 11/9/12 12/20/12 $230 A 100% subsidiary of Sun

January | February | March | April | May | June | July | August | September | October | November | December COMPLETED MERGERS AND ACQUISITIONS - December 2011 Company Acquired Acquired By Or Merged With Date Announced Date Completed Value (M) Terms/Details Adagio Pharmaceuticals Ltd. Cynapsus Therapeutics Inc. 8/18/11 12/28/11 $1.3 Cynapsus acquired Adagio with 26M common shares with a deemed value of 5 cents per share Adolor Corp. Cubist Pharmaceuticals Inc

January | February | March | April | May | June | July | August | September | October | November | December | December - 2011 Biotech Company Pharma Company Type/Product Area Terms/Details Akorn Inc. H. Lundbeck A/S Akorn's subsidiary, Oak Pharmaceuticals, acquired three off-patent, branded, hospital-based injectables Akorn will make an up-front payment of $45M and a subsequent milestone payment of $15M in cash after three years Amgen Inc. Watson Pharmaceuticals Inc. Deal to develop

January | February | March | April | May | June | July | August | September | October | November | December | December - 2011 Company Company Type/Product Area Terms/Details Ampio Pharmaceuticals Inc. Undisclosed party Deal to acquire rights to a patented orally disintegrating tablet drug delivery technology for use with Zertane, its candidate for premature ejaculation Financial terms were not disclosed AtheroNova Inc. OOO CardioNova (Russian subsidiary of Maxwell Biotech

Public Companies | Private Companies PUBLIC COMPANIES - December 2011 Company (Symbol) Type Of Financing Number Of Shares, Units Or Warrants (M) Amount Raised (US$M) Allon Therapeutics Inc. Investment N/A $5.44 Ampio Pharmaceuticals Inc. Registered direct offering 2S $9.5 ARCA Biopharma Inc. Private placement of common stock and warrants 1.67U $1.75 Cell Therapeutics Inc. Registered direct offering 17.4S and W for 6.96S $8.8 Celsion Corp. Private

Follow-on Offerings FOLLOW-ON OFFERINGS - December 2011 Company Date Filed Date Comm. Shares/Units (M) Price Gross (M) Ariad Pharmaceuticals Inc. 12/14/11 12/15/11 24.7S $10.42 $257.37 Gilead Sciences Inc. (GILD) 3/23/11 12/8/11 Notes N/A $3.7B Inovio Pharmaceuticals Inc. (AMEX:INO) 9/2/11 12/1/11 7.7U $0.5195 $4 Novelos Therapeutics Inc. (OTCQB:NVLT) 12/2/11 12/2/11 10.08U $0.60 $6.048 Orexigen Therapeutics Inc. (OREX) 9/17/09 12/15/11 5.65U $15.94 $90 StemCells Inc. (STEM) 11/3/10 12/16

Commenced Trading COMMENCED TRADING - December 2011 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) No initial public offerings have commenced in December. COMMENCED TRADING - November 2011 INITIAL OFFERINGS Company Date Filed Date Comm. Shares/Units (M) Price Shares Out (M) Gross (M) Clovis Oncology Inc. (CLVS) 6/23/11 11/15/11 10.7S $13 22.4 $139.1 NewLink Genetics Corp. (NLNK) 12/21/10 11/11/11

January | February | March | April | May | June | July | August | September | October | November | December | December - 2010 Company Company Type/Product Area Terms/Details Adimab Inc. Genentech Inc. (NYSE:DNA), Human Genome Sciences Inc. (HGSI) and Eli Lilly and Co. Adimab initiated three new research collaborations for the use of its antibody discovery platform technology Financial terms were not disclosed Advanced Cell Technology Inc. (OTC BB:ACTC) Roslin Cells Ltd